EXECUTIVE ENGAGEMENTS
POOL
INTERACTIONS
PARTICIPANTS
VALIDATIONS
COMPANIES
* Login for a full stack data experience
DATE
FEB 2022
TABLES
34
PAGES
334
EDITION
3
PRICE
USD 5600
CODE
MCP23108
*Engagement stats are ongoing and dynamic
HIGHLIGHTS & REPORT INDEX
What`s New for 2022?
» Global competitiveness and key competitor percentage market shares
» Market presence across multiple geographies - Strong/Active/Niche/Trivial
» Online interactive peer-to-peer collaborative bespoke updates
» Access to our digital archives and MarketGlass Research Platform
» Complimentary updates for one year
The ongoing Covid-19 pandemic has highlighted the potential for mRNA therapies. The mRNA technology has experienced decades of research efforts from scientists and various biotechnology companies. Discovered in the 1960s as an option to convert DNA codes into proteins, mRNA took several decades to emerge as promising therapeutic modality for various medical conditions. mRNA medicines make use of the usual biological processes to extract proteins and create the required therapeutic effect, due to which the treatment of several diseases that cannot be achieved using current technologies is made easy. mRNA therapeutics have gained major attention following the development of new synthesis as well as delivery approaches. The advances in the generation, purification and cellular delivery of RNA have widened the scope of RNA-based therapeutics for a broad array of applications. The technology is marked by its compelling advantages over traditional methods in terms of turnaround times, production speed and cost savings. Various clinical and preclinical studies have indicated promising results for protein replacement therapies, prevention of infectious diseases, tumor immunotherapy and cancer vaccines. In the historic global race to develop a vaccine, mRNA based Covid-19 vaccine from Moderna and Pfizer stand out as frontrunners. The unique characteristics of mRNA has made it of great interest to vaccine developers. While traditional vaccines have used live or inactivated pathogens to elicit an immune response, mRNA is responsible for cellular processes, building structures, regulating functions, and building structural components. mRNA vaccines work by introducing a part of mRNA that reacts to the viral protein. It accelerates production of antibodies and trains the immune system to recognize the virus in the future, thereby offering protection. Essentially a chemical process, production of mRNA vaccines eliminates the need for growing proteins or viruses, a key reason why vaccines by Moderna and Pfizer/BioNTech quickly reached human trials. For instance, Moderna`s vaccine was created in just six weeks. Securing approval for emergency use, the two vaccines demonstrated around 95% efficacy in eliciting immune response against the COVID-19 virus during clinical trials. The global market for mRNA vaccines is projected to reach US$131.3 Billion by 2026.
Beyond Covid-19, mRNA-based therapies hold promise for combatting cancer, infectious diseases such as malaria and flu, and rare genetic diseases. Results from early animal testing demonstrates the ability of mRNA-based therapeutics to provide protection against viruses such as influenza, Zika and rabies. With the effectiveness of mRNA vaccines against Covid-19, there is heightened research interest in pursuing mRNA platform for treating infectious diseases, for example, BioNTech is preparing to launch the first vaccine for malaria based on mRNA technology with plans to conduct clinical testing by the end of 2022. Similarly, Moderna also announced plans to conduct human trials for an HIV vaccine. Currently, of the total 44 ongoing clinical trials of mRNA vaccines, 23 of them are aimed at infectious diseases. Cancer research has used mRNA platform to trigger the immune system to target specific cancer cells. Currently, there are many clinical trials underway utilizing mRNA vaccines for various cancers. Most of the mRNA cancer vaccine trials are targeting tumors such as melanoma and kidney cancer. An mRNA vaccine could be custom-made to match the genetic signature of an individual`s cancer. This personalized mRNA vaccine could be used following surgery to program the immune system to search out and destroy any residual cancer cells, and thus prevent the cancer from recurring. For instance, the pipelines of Moderna and BioNTech include drug trials for treating cancers of the brain, breast, prostate, pancreas, lung, skin and other tissues. The mRNA vaccines market is projected to receive notable contribution from the cancer segment that is estimated to claim the leading revenue share over the coming years. The segment`s growth is augmented by increasing incidence of cancer. The condition remains one of the major causes of mortalities globally, with the number of new cases annually exceeding 23.6 million by the year 2030.
mRNA is also being pursued to aid in rapid development of drugs for rare diseases. Recent advancements in the structural composition of mRNA have led the scientific community to swiftly embrace it as a new drug to deliver missing genes to organs. The pipelines of Moderna, CureVac and BioNTech, three major biopharmaceutical companies, cover heart diseases, metabolic diseases and immunomodulators for applications in immuno-oncology. The introduction of synthetic mRNA into human cells opens scope for a replacement therapeutic option for conditions known for defective or inadequate synthesis of key proteins. The approach holds significant potential over protein replacement and gene therapies owing to its lower risk, affordability and less frequent dosage. mRNA can be used as protein replacement therapy to treat diseases caused by a lack of protein, or by defective proteins. Many mRNA-based protein replacement therapies are under development for the heart, lungs and liver. For example, Cardior Pharmaceuticals, a Germany-based biotechnology company, is working on RNA drugs for treatment of heart failure. Translate Bio developed a protein replacement therapy for cystic fibrosis, which is currently undergoing Phase 1/2 clinical trial. In addition, mRNA is being explored as potential alternative to gene therapy for treatment of intractable medical conditions like sickle cell disease. Early studies on animal models have demonstrated the potential of mRNA vaccines to combat viruses such as Zika, rabies and influenza. While researchers are working on an mRNA-based vaccine for malaria and dengue virus, BioNTech is looking forward to conduct clinical trials for its mRNA-based vaccine for malaria by the end of 2022. Increased scientific interest and funding brought on by the pandemic is expected to further boost advancements in mRNA vaccine and therapeutics technologies. The widespread recognition is leading to new uses of mRNA being developed and approved.
SELECT PLAYERS
BioNTech AG; CureVac AG; Dicerna Pharmaceuticals; eTheRNA Immunotherapies; ethris GmbH; In-Cell-Art; Moderna, Inc.; Regulus Therapeutics; Sangamo Therapeutics, Inc.; Tiba Biotech; Translate Bio, Inc.
SEGMENTS
» Indication (COVID-19 Vaccine, Cancer Vaccine, Other Indications)
GEOGRAPHIES
» World » USA » Canada » Japan » China » Europe » France » Germany » Italy » UK » Rest of Europe » Asia-Pacific » Rest of World
TABLE OF CONTENTS
I. METHODOLOGY |
II. EXECUTIVE SUMMARY |
1. MARKET OVERVIEW |
Impact of Covid-19 and a Looming Global Recession |
The Race Between the Virus & Vaccines Intensifies |
Effectiveness of Vaccinations |
Covid-19 Vaccine Shortages Hit Global Supply Initiative |
Saving Lives with Vaccines |
Dosing Interval Adjustment to Expand Coverage |
Global COVID-19 Vaccine Inequity |
Accessibility of Vaccines |
Impact of Vaccine Inequity on the Economy |
Impact of Vaccine Inequity on the Labor Market |
Financing Vaccines |
mRNA Platform – Global Key Competitors Percentage Market Share in 2023 (E) |
Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2023 (E) |
MRNA - A CONCEPTUAL UNDERSTANDING |
MRNA: A New Approach to Medicine |
Long Wait & Scientific Breakthroughs |
mRNA Vaccines - An Introduction |
With Unparalleled Turnaround Time, mRNA Platform Adds Revolutionary Dimension to Vaccine Development |
mRNA: Making Cells Act as Vaccine Factory |
mRNA Vaccines: Advantages |
mRNA Vaccines: Cons |
mRNA Vaccine Approvals |
A Comparison of Pfizer, Moderna, and AstraZeneca COVID-19 Vaccine |
Traditional Vs. mRNA Vaccines: Key Differences |
Traditional Vs. mRNA Vaccines: The Development Process |
How mRNA Vaccine Works & Earlier Testing Efforts |
mRNA Vaccines: Safety Quotient |
Other Notable Efforts Centered on mRNA Technology |
Overcoming Challenges |
As Serious Candidate, mRNA Technology Warrants Attention from Scientific Community |
GLOBAL MARKET OVERVIEW |
Global mRNA Vaccines Market on a Dynamic Growth Track |
Riding COVID-19 Wave, mRNA Vaccines Take Center Stage & See Exciting Times Ahead |
COVID-19 mRNA Vaccine Approval Details |
COVID-19 Funding Details of Moderna and Pfizer Vaccine |
EXHIBIT: Production Capacity of mRNA Frontrunners in Millions of Doses for 2021 |
COVID-19 Pandemic: An Eventful Year for RNA |
COVID-19’s Impact on Vaccine Development – A Transformative Shift to mRNA vaccines |
mRNA Based Vaccines in Clinical Development |
EXHIBIT 7: Vaccines in Pipeline by Technology |
EXHIBIT 14: Vaccine Technologies in Pre-Clinical Studies |
VARIOUS VIRUS VARIANTS |
COVID-19 Virus Can Adapt & Undergo ‘Escape Mutation’ to Pose Vaccine Challenge |
Indian Variant of COVID-19 Virus Puts Healthcare System on Brink of Major Collapse |
Investigating the Virulence Profile of India’s N440K Variant |
Is South African Variant a Formidable Threat? |
E484K Mutation Challenges Vaccine Developers |
Rising Cases in South Africa & Other Countries |
California Strain Emerges to be More Contagious and Deadly |
Pfizer COVID-19 Vaccine Demonstrates Low to Modest Level of Efficacy against South African Variant |
Moderna’s Variant-Specific Vaccine Candidate Ready for Clinical Study |
mRNA Vaccines Could Vanquish Cancer and Other Diseases, Cancer Segment to Make Major Contribution to Global mRNA Vaccines Market |
The US Holds Leading Position, while Asia-Pacific Exhibits Lucrative Growth in mRNA Vaccines Market |
Faster, Effective and Cheaper: Adaptability of mRNA Vaccine Unleashes Potential Utility for Developing Nations |
RECENT MARKET ACTIVITY IN THE COVID-19 VACCINE SPACE |
Pfizer and BioNTech’s COVID-19 Vaccine Receives World’s First Authorization |
UK Clinches the First Position in the World to Approve Pfizer’s Vaccine |
After UK, US Gives Nod to Pfizer’s Vaccine |
EU Approves Pfizer’s Vaccine |
BioNTech to Scale up Vaccine Production to Fill Supply Gaps and Support Vaccination Efforts in the EU |
Novartis Inks Agreement with Pfizer-BioNtech to Support Covid-19 Vaccine Production |
FDA Approves Pfizer-BioNTech Vaccine in Kids aged 12 to 15 Years Age (May, 2021) |
Moderna’s mRNA Vaccine Bags Approval from US FDA |
Moderna Kick-Starts Inoculation in the US |
FDA Approves Pfizer-BioNTech Vaccine in Kids aged 12 to 15 Years Age (May, 2021) |
Moderna Begins Testing its Vaccine on Children Aged Below 12 Years (March, 2021) |
Recent Market Activity |
COMPETITIVE SCENARIO |
BioNTech – A Pioneer in mRNA-based Vaccines and Therapies |
List of BioNTech’s mRNA Candidates in Clinical Trials for Cancer |
Moderna’s Ambitious Stride into Vaccine Development: From a Novice to Know All |
Moderna’s mRNA Prophylactic Vaccines |
mRNA Cancer Vaccines |
mRNA Intratumoral Immuno-Oncology |
mRNA Systemic Secreted & Cell Surface Therapeutics |
mRNA Systemic Intracellular Therapeutics |
Sanofi Commences Clinical Trials of mRNA vaccine for Covid-19 |
mRNA as Promising Vaccine Technology Entices Startups to Join the Bandwagon |
Noteworthy Startups Exploiting mRNA Technology |
The East Falls behind the West in Embracing the Revolutionary mRNA Technology for Developing Vaccines to Fight against COVID-19 |
2. FOCUS ON SELECT PLAYERS |
3. MARKET TRENDS & DRIVERS |
Rising Incidence of Coronavirus Cases Drive the Market Demand |
Increasing Prevalence of Infectious & Chronic Conditions to Unleash Gains & Help mRNA Vaccines Market Gallop Ahead |
mRNA Vaccines Development for Other Infectious Diseases and Therapeutic Areas Gains Momentum |
EXHIBIT 8: Worldwide Cancer Incidence: Number of New Cancer Cases Diagnosed for 2012, 2018 & 2040 |
EXHIBIT 10: Global HIV Prevalence: Number of People Living with AIDs (in Thousands) by Region for 2018 |
EXHIBIT 11: Number of AIDS-Related Deaths (in Thousands) by Region for 2018 |
Aging Demographics Add to the Global Burden of Chronic Diseases, Presenting Opportunities for the Market |
EXHIBIT: Global Aging Population Statistics for the 65+ Age Group in Million by Geographic Region for the Years 2019, 2025, 2035 and 2050 |
EXHIBIT: Elderly Population (65+ Years) as a % of Total Population by Developed, Less Developed and Least Developed Regions: 2019 & 2030 |
Increasing Healthcare Expenditure to Foster Market Growth |
EXHIBIT 2: World Healthcare Expenditure (In US$ Billion) for the Years 2017-2023 |
EXHIBIT 3: Healthcare Costs as a % of GDP by Country for the Years 2020 & 2023 |
Consistent Increase in Risks and Threats from Infections Drive Healthy Market Growth |
EXHIBIT 5: Global Number of Deaths Caused Due to Communicable Diseases (In 000s) |
Regulatory Landscape for mRNA Vaccines |
Regulatory Pathway Dealing with mRNA Vaccines |
mRNA Vaccine Patent Scenario |
The Best Route of Administration for mRNA Vaccines |
CDC Study on Vaccine Effectiveness States mRNA Vaccines Offer More Protective Benefits than other Vaccines (March, 2021) |
mRNA CANCER VACCINES |
Introduction |
Cancer Vaccines Vs. Immunotherapies |
EXHIBIT: Clinical Trials of mRNA Encoding Immunostimulants |
mRNA Vaccines Vs. DNA Vaccines |
EXHIBIT: Clinical Trials of mRNA Encoding TAAs |
mRNA Vaccines Vs. Other Vaccines |
EXHIBIT: Clinical Trials of mRNA Vaccines Encoding Neoantigens (Neo-Ag) |
mRNA Benefits Profile |
mRNA Vaccines for Covid-19 Pave the Way |
Challenges |
Personalized mRNA Vaccine |
Clinical Overview of mRNA Cancer Vaccines |
mRNA encoding Immunostimulants |
mRNA vaccine encoding tumor-associated antigens |
mRNA vaccine encoding Neoantigen, personalized vaccine |
mRNA Influenza Vaccines |
Perpetual Evolution of Influenza Viruses Makes mRNA a Fascinating Vaccine Platform |
Vaccines Built on mRNA |
Clinical Trials for mRNA Vaccines |
mRNA Vaccine as Game Changer for Flu Viruses Eluding Conventional Vaccine Efforts |
mRNA: A Next-Generation Vaccination Approach |
Moderna Moves Ahead to Brew Novel mRNA Vaccines for Influenza & Other Viruses |
COVID-19 Vaccine Technology to Foster Development of Effective Flu Shots |
mRNA Vaccines Vs. Other Flu Shots |
mRNA Technology, H/N Spike Proteins & Clinical Trials |
mRNA Technology: A Suitable Candidate for Universal & Effective Influenza Vaccines |
Benefits & Limitations of mRNA Vaccines over Traditional Options |
4. GLOBAL MARKET PERSPECTIVE |
World Recent Past, Current & Future Analysis for mRNA Platform by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2021 through 2027 and % CAGR |
World 6-Year Perspective for mRNA Platform by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2022 & 2027 |
World Recent Past, Current & Future Analysis for Covid-19 Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2021 through 2027 and % CAGR |
World 6-Year Perspective for Covid-19 Vaccine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2022 & 2027 |
World Recent Past, Current & Future Analysis for Cancer Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2021 through 2027 and % CAGR |
World 6-Year Perspective for Cancer Vaccine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2022 & 2027 |
World Recent Past, Current & Future Analysis for Other Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2021 through 2027 and % CAGR |
World 6-Year Perspective for Other Indications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2022 & 2027 |
III. MARKET ANALYSIS |
UNITED STATES |
mRNA Platform Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2023 (E) |
US FDA Gives Nod to Pfizer and Moderna’s mRNA Vaccines |
Moderna to Supply 100 Million more Doses of COVID-19 Vaccine to the US Government |
Lonza Announces Plans to Double Moderna COVID-19 Vaccine Output in Switzerland |
US Regulators Give Nod to Pfizer-BioNTech COVID-19 Vaccine for Ages 12 to 15 |
Sanofi Joins Hands with Moderna to Produce COVID-19 Vaccines for Global Supply |
USA Recent Past, Current & Future Analysis for mRNA Platform by Indication - Covid-19 Vaccine, Cancer Vaccine and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2021 through 2027 and % CAGR |
USA 6-Year Perspective for mRNA Platform by Indication - Percentage Breakdown of Value Sales for Covid-19 Vaccine, Cancer Vaccine and Other Indications for the Years 2022 & 2027 |
CANADA |
Vaccination Gathers Steam Across Canada |
EXHIBIT 21: Percentage (%) of Population Vaccinated (at least one dose) in Canada by Province/Territory As of May 3, 2021 |
COVID-19 Vaccine Deals in Canada |
Pfizer Plans to Ramp up COVID-19 Vaccine Supply to Canada from May, 2021 |
Canada Grants Approval to Pfizer’s COVID-19 Shot for Use in Children in 12-15 Years Age Group |
Canada Recent Past, Current & Future Analysis for mRNA Platform by Indication - Covid-19 Vaccine, Cancer Vaccine and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2021 through 2027 and % CAGR |
Canada 6-Year Perspective for mRNA Platform by Indication - Percentage Breakdown of Value Sales for Covid-19 Vaccine, Cancer Vaccine and Other Indications for the Years 2022 & 2027 |
JAPAN |
mRNA Platform Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2023 (E) |
COVID-19 Vaccination Programs in Japan Move Forward at Snail’s Pace |
Reasons Responsible for Setback |
Vaccine Timeline & Availability |
Japan Demands for Vaccine-Related Data |
People’s Low Trust in Vaccines |
Japan’s Efforts to Develop Indigenous Vaccines |
Japan to Step Up COVID-19 Immunization Drive to Cover Geriatric Population |
Japan Inks Deal with Pfizer to Secure 50 Million Additional Doses of COVID-19 Vaccine |
Japan Pushes Shipments of Pfizer’s COVID-19 Shots to Vaccinate Elderly |
Japan Recent Past, Current & Future Analysis for mRNA Platform by Indication - Covid-19 Vaccine, Cancer Vaccine and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2021 through 2027 and % CAGR |
Japan 6-Year Perspective for mRNA Platform by Indication - Percentage Breakdown of Value Sales for Covid-19 Vaccine, Cancer Vaccine and Other Indications for the Years 2022 & 2027 |
CHINA |
mRNA Platform Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2023 (E) |
BioNTech’s Shot to Become First Western COVID-19 Vaccine to Secure Authorization in China |
China Recent Past, Current & Future Analysis for mRNA Platform by Indication - Covid-19 Vaccine, Cancer Vaccine and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2021 through 2027 and % CAGR |
China 6-Year Perspective for mRNA Platform by Indication - Percentage Breakdown of Value Sales for Covid-19 Vaccine, Cancer Vaccine and Other Indications for the Years 2022 & 2027 |
EUROPE |
mRNA Platform Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2023 (E) |
EU Urges Nations to Focus on COVID-19 Vaccine Sharing & Export to Beat the Pandemic (May, 2021) |
COVID-19 Vaccine Drive Gathers Pace in Europe after Initial Glitch |
EU Approves Pfizer’s Vaccine |
EU Eyes on Milestone Deal to Get 1.8 Billion Doses of Pfizer-BioNTech COVID-19 Vaccine |
European Agency Makes Changes to Ramp Up Supply & Manufacturing Capacity of Pfizer & Moderna COVID-19 Vaccines |
BioNTech to Scale up Vaccine Production to Fill Supply Gaps and Support Vaccination Efforts in the EU |
Europe Recent Past, Current & Future Analysis for mRNA Platform by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2021 through 2027 and % CAGR |
Europe 6-Year Perspective for mRNA Platform by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2022 & 2027 |
Europe Recent Past, Current & Future Analysis for mRNA Platform by Indication - Covid-19 Vaccine, Cancer Vaccine and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2021 through 2027 and % CAGR |
Europe 6-Year Perspective for mRNA Platform by Indication - Percentage Breakdown of Value Sales for Covid-19 Vaccine, Cancer Vaccine and Other Indications for the Years 2022 & 2027 |
FRANCE |
mRNA Platform Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2023 (E) |
France Recent Past, Current & Future Analysis for mRNA Platform by Indication - Covid-19 Vaccine, Cancer Vaccine and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2021 through 2027 and % CAGR |
France 6-Year Perspective for mRNA Platform by Indication - Percentage Breakdown of Value Sales for Covid-19 Vaccine, Cancer Vaccine and Other Indications for the Years 2022 & 2027 |
GERMANY |
mRNA Platform Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2023 (E) |
Germany Recent Past, Current & Future Analysis for mRNA Platform by Indication - Covid-19 Vaccine, Cancer Vaccine and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2021 through 2027 and % CAGR |
Germany 6-Year Perspective for mRNA Platform by Indication - Percentage Breakdown of Value Sales for Covid-19 Vaccine, Cancer Vaccine and Other Indications for the Years 2022 & 2027 |
ITALY |
Italy Plans to Produce mRNA Vaccines Domestically |
Italy Recent Past, Current & Future Analysis for mRNA Platform by Indication - Covid-19 Vaccine, Cancer Vaccine and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2021 through 2027 and % CAGR |
Italy 6-Year Perspective for mRNA Platform by Indication - Percentage Breakdown of Value Sales for Covid-19 Vaccine, Cancer Vaccine and Other Indications for the Years 2022 & 2027 |
UNITED KINGDOM |
mRNA Platform Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2023 (E) |
Market Analysis |
UK Wins COVID-19 Vaccine Race with Approval of Pfizer-BioNTech Vaccine |
Moderna Modifies Supply Contract with UK to Deliver Additional Doses of COVID-19 Vaccine |
UK’s Independent Vaccine Deals |
UK Recent Past, Current & Future Analysis for mRNA Platform by Indication - Covid-19 Vaccine, Cancer Vaccine and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2021 through 2027 and % CAGR |
UK 6-Year Perspective for mRNA Platform by Indication - Percentage Breakdown of Value Sales for Covid-19 Vaccine, Cancer Vaccine and Other Indications for the Years 2022 & 2027 |
REST OF EUROPE |
Rest of Europe Recent Past, Current & Future Analysis for mRNA Platform by Indication - Covid-19 Vaccine, Cancer Vaccine and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2021 through 2027 and % CAGR |
Rest of Europe 6-Year Perspective for mRNA Platform by Indication - Percentage Breakdown of Value Sales for Covid-19 Vaccine, Cancer Vaccine and Other Indications for the Years 2022 & 2027 |
ASIA-PACIFIC |
mRNA Platform Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2023 (E) |
INDIA |
Pfizer Looks Forward to Make its COVID-19 Vaccine Available in India |
AUSTRALIA |
Australia to Buy 20 Million Extra Doses of Pfizer COVID-19 Vaccine, Pivoting away from AstraZeneca |
NEW ZEALAND |
New Zealand Acquires Ultra-Cold Freezers to Store Pfizer’s COVID-19 Vaccine |
Asia-Pacific Recent Past, Current & Future Analysis for mRNA Platform by Indication - Covid-19 Vaccine, Cancer Vaccine and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2021 through 2027 and % CAGR |
Asia-Pacific 6-Year Perspective for mRNA Platform by Indication - Percentage Breakdown of Value Sales for Covid-19 Vaccine, Cancer Vaccine and Other Indications for the Years 2022 & 2027 |
REST OF WORLD |
THE MIDDLE EAST |
BAHRAIN |
Bahrain Becomes the Second Country to Offer Emergency Use Approval to Pfizer’s Vaccine |
AFRICA |
SOUTH AFRICA |
New Virus Variant in South Africa Creates a Challenge |
Highly Infectious COVID-19 Variant Spurs Countries to Impose Travel Ban from South Africa |
LATIN AMERICA |
Mass COVID-19 Vaccination Campaigns Launched in Latin American Countries |
BRAZIL |
Brazil Signs Deal to Buy Additional 100 Million Doses from Pfizer/BioNTech |
MEXICO |
Mexico’s Cofepris Approves Emergency Use of Pfizer's COVID-19 Vaccine |
Rest of World Recent Past, Current & Future Analysis for mRNA Platform by Indication - Covid-19 Vaccine, Cancer Vaccine and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2021 through 2027 and % CAGR |
Rest of World 6-Year Perspective for mRNA Platform by Indication - Percentage Breakdown of Value Sales for Covid-19 Vaccine, Cancer Vaccine and Other Indications for the Years 2022 & 2027 |
IV. COMPETITION |
Total Companies Profiled: 96 |
PREVIEW REPORT
Our robust permission-based engagement strategy requires a one-time double opt-in and/or re-consent for all users. We will re-establish consent once a year from date of last use. Both these practices exceed GDPR mandates.
What we store: Primary coordinates such as email, company address and phone. In-house developed influencer rank.
How we store: Encrypted and additionally secured by firewalls.
How we use your data: Only to contact you directly. We never share your coordinates with any individual or entity outside our company for any reason.
Privacy queries: Privacy@StrategyR.com